Publications by authors named "Mohammad Azab"

Claim this Profile
S
Synthesis, antiproliferative screening, and molecular docking of some heterocycles derived from N-(1-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-hydrazineyl-3-oxoprop-1-en-2-yl)benzamide.
Eman A E El-Helw, Youssef M Youssef, Galal A Elsayed, Amira A El-Sayed, Aya I Hassaballah, Mohammad E Azab

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissociation between the expression of cGAS/STING and a senescence-associated signature in colon cancer.
Sofian Al Shboul, Ola Abu Al Karsaneh, Moath Alrjoub, Mohammad Al-Qudah, Mohammed El-Sadoni, Mohammad Al-Azab

Int J Immunopathol Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Mohammad Azab

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Mohammad Azab

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and in silico studies of certain benzo[f]quinoline-based heterocycles as antitumor agents.
Eman A E El-Helw, Mahmoud Asran, Mohammad E Azab, Maher H Helal, Abdullah Y A Alzahrani

Sci Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Gail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, Karen Yee, Hagop Kantarjian, Mohammad Azab

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Mohammad Azab

Lancet Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J Roboz, Mohammad Azab

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J Roboz, Mohammad Azab

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Pierre Fenaux, Marco Gobbi, Patricia L Kropf, Jean-Pierre J Issa, Gail J Roboz, Mohammad Azab

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified Lateral Orbitotomy Approach to Lesions of the Orbital Apex, Superior Orbital Fissure, Cavernous Sinus, and Middle Cranial Fossa.
Michael T Bounajem, Robert C Rennert, Karol P Budohoski, Mohammad Azab, Michael Karsy

Oper Neurosurg· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Reply to the Letter to Editor Regarding "Case Series and Systematic Review of Electronic Scooter Crashes and Severe Traumatic Brain Injury".
Mohammad Azab, Nicholas Gamboa, Jeffrey Nadel, Christopher Cutler, Brandon Lucke-Wold

World Neurosurg· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of Optical Biosensors for Early Cancer Detection: Fundamentals, Applications and Future Perspectives.
Mohammad Y Azab, Mohamed Farhat O Hameed, Salah S A Obayya

Biology (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Series and Systematic Review of Electronic Scooter Crashes and Severe Traumatic Brain Injury.
Mohammad Azab, Nicholas Gamboa, Jeffrey Nadel, Christopher Cutler, Jeffrey Curran Henson

World Neurosurg· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Mohammad Azab

Blood· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Swapna Thota, Aram Oganesian, Mohammad Azab, Elizabeth A Griffiths

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the factors influencing healthcare providers' burnout during the outbreak of COVID-19 in Jordanian hospitals.
Abdullah Algunmeeyn, Faris El-Dahiyat, Mohammad Mitib Altakhineh, Mohammad Azab, Zaheer-Ud-Din Babar

J Pharm Policy Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Guillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, Gail J Roboz, Richard Wells, Mohammad Azab

Blood· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Haley E Ramsey, Aram Oganesian, Agnieszka E Gorska, Londa Fuller, Maria Arrate, Mohammad Azab

Target Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D Roman, Mohammad Azab

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello, Dietmar Rieder, Riccardo Danielli, Mohammad Azab

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Woonbok Chung, Andrew D Kelly, Patricia Kropf, Henry Fung, Jaroslav Jelinek, Mohammad Azab

Clin Epigenetics· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Mohammad Azab

Lancet Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Michael R Savona, Olatoyosi Odenike, Philip C Amrein, David P Steensma, Amy E DeZern, Mohammad Azab

Lancet Haematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Molecular Docking Study of Novel Heterocycles Incorporating 1,3,4-Thiadiazole Moiety as Potential Antimicrobial and Anticancer Agents.
Mohamed El-Naggar, Hanan A Sallam, Safaa S Shaban, Salwa S Abdel-Wahab, Abd El-Galil E Amr, Mohammad E Azab

Molecules· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis